Lupin gets USFDA EIR for Somerset facility
The USFDA has determined that the inspection classification of the facility is Voluntary Action Indicated (VAI).
Somerset: Global pharma major, Lupin Limited, today announced that the company has received the Establishment Inspection Report (EIR) from United States Food and Drug Administration (USFDA) for its Somerset, NJ manufacturing facility, after the inspection of the facility in March 2022.Voluntary Action Indicated (VAI) means objectionable conditions or practices were found but the agency is...
Somerset: Global pharma major, Lupin Limited, today announced that the company has received the Establishment Inspection Report (EIR) from United States Food and Drug Administration (USFDA) for its Somerset, NJ manufacturing facility, after the inspection of the facility in March 2022.
Voluntary Action Indicated (VAI) means objectionable conditions or practices were found but the agency is not prepared to take or recommend any administrative or regulatory action.
The USFDA has determined that the inspection classification of the facility is Voluntary Action Indicated (VAI).
"We are very happy to have received the EIR from US FDA with satisfactory VAI classification for our Somerset facility. This is a significant milestone for our Somerset site, and an important step in our journey to build back our reputation as best in class in Quality and Compliance. We are committed to manufacture and supply products of the highest quality for the patients we serve," said Vinita Gupta, CEO, Lupin.
Commenting on the development, Nilesh Gupta, Managing Director, Lupin said, "We remain committed to meet and exceed global standards of Quality and Compliance at all our manufacturing sites. We are very happy to have received the EIR for our Somerset facility with Voluntary Action Indicated status from US FDA. With this positive development, we now look forward towards building a sustainable business from our Somerset facility, and carry this momentum to positive outcomes for our other sites."
Read also: Cipla Indore plant gets 2 USFDA observations
Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement/treatment or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2024 Minerva Medical Treatment Pvt Ltd